1620 related articles for article (PubMed ID: 10778981)
21. Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1.
Darbinian N; Gallia GL; Kundu M; Shcherbik N; Tretiakova A; Giordano A; Khalili K
Oncogene; 1999 Nov; 18(46):6398-402. PubMed ID: 10597240
[TBL] [Abstract][Full Text] [Related]
22. Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells.
Sala A; Nicolaides NC; Engelhard A; Bellon T; Lawe DC; Arnold A; Graña X; Giordano A; Calabretta B
Cancer Res; 1994 Mar; 54(6):1402-6. PubMed ID: 8137237
[TBL] [Abstract][Full Text] [Related]
23. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
24. The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.
O'Connor RJ; Schaley JE; Feeney G; Hearing P
Oncogene; 2001 Apr; 20(15):1882-91. PubMed ID: 11313936
[TBL] [Abstract][Full Text] [Related]
25. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
26. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter.
Rotheneder H; Geymayer S; Haidweger E
J Mol Biol; 1999 Nov; 293(5):1005-15. PubMed ID: 10547281
[TBL] [Abstract][Full Text] [Related]
27. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
28. The role of p16 in the E2F-dependent thymidine kinase regulation.
Hengstschläger M; Hengstschläger-Ottnad E; Pusch O; Wawra E
Oncogene; 1996 Apr; 12(8):1635-43. PubMed ID: 8622883
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
30. E2F-1 and E2F-3 are functionally distinct in their ability to promote myeloid cell cycle progression and block granulocyte differentiation.
Strom DK; Cleveland JL; Chellappan S; Nip J; Hiebert SW
Cell Growth Differ; 1998 Jan; 9(1):59-69. PubMed ID: 9438389
[TBL] [Abstract][Full Text] [Related]
31. Isolation and characterization of a chicken homolog of the E2F-1 transcription factor.
Pasteau S; Loiseau L; Arnaud L; Trembleau A; Brun G
Oncogene; 1995 Oct; 11(8):1475-86. PubMed ID: 7478572
[TBL] [Abstract][Full Text] [Related]
32. Regulation of dihydrofolate reductase gene expression and E2F components in human diploid fibroblasts during growth and senescence.
Good L; Dimri GP; Campisi J; Chen KY
J Cell Physiol; 1996 Sep; 168(3):580-8. PubMed ID: 8816912
[TBL] [Abstract][Full Text] [Related]
33. Involvement of retinoblastoma (Rb) and E2F transcription factors during photodynamic therapy of human epidermoid carcinoma cells A431.
Ahmad N; Gupta S; Mukhtar H
Oncogene; 1999 Mar; 18(10):1891-6. PubMed ID: 10086343
[TBL] [Abstract][Full Text] [Related]
34. Functional roles of E2F in cell cycle regulation.
Fan J; Bertino JR
Oncogene; 1997 Mar; 14(10):1191-200. PubMed ID: 9121768
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
37. Changes in E2F DNA-binding activity during induced erythroid differentiation.
Richon VM; Venta-Perez G
Cell Growth Differ; 1996 Jan; 7(1):31-42. PubMed ID: 8788031
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
39. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
[TBL] [Abstract][Full Text] [Related]
40. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
